Dose-Escalated Radn Does Not Up Survival in Localized Prostate CA

Share this content:
Dose-Escalated Radn Does Not Up Survival in Localized Prostate CA
Dose-Escalated Radn Does Not Up Survival in Localized Prostate CA

FRIDAY, March 16, 2018 (HealthDay News) -- Dose escalation from 70.2 to 79.2 Gy is not associated with improved overall survival (OS) in intermediate-risk prostate cancer, according to a study published online March 15 in JAMA Oncology.

Jeff M. Michalski, M.D., from Washington University in St. Louis, and colleagues randomized 1,532 men with stage cT1b to T2b, Gleason score 2 to 6, and prostate-specific antigen (PSA) level of ≥10 and <20 or Gleason score of 7 and PSA <15 to 79.2 Gy radiation therapy in 44 fractions or 70.2 Gy in 39 fractions.

The researchers observed no difference in OS for the 751 men in the 79.2-Gy arm and the 748 men in the 70.2-Gy arm, with a median follow-up of 8.4 years. The eight-year rates of OS were 76 and 75 percent with 79.2 and 70.2 Gy, respectively (hazard ratio, 1.00; 95 percent confidence interval, 0.83 to 1.20; P = 0.98). The eight-year cumulative rates of distant metastases were 4 and 6 percent for the 79.2- and 70.2-Gy arms, respectively (hazard ratio, 0.65; 95 percent confidence interval, 0.42 to 1.01; P = 0.05). The ASTRO and Phoenix biochemical failure rates at five and eight years were significantly higher with 70.2 than 79.2 Gy. The rate of salvage therapy use was lower in the high-dose arm.

"Despite improvements in biochemical failure and distant metastases, dose escalation did not improve OS," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

USPSTF Urges Abuse Screening for Reproductive-Aged Women

USPSTF Urges Abuse Screening for Reproductive-Aged Women

Evidence lacking for assessing balance of benefits, harms of screening for abuse of seniors, vulnerable

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Increased likelihood of clinical and microbiological resolution for uncomplicated UTI in women

Exercise Intervention Doesn't Improve Walking Ability in PAD

Exercise Intervention Doesn't Improve Walking Ability in PAD

Smaller mean change from baseline to follow-up in 6-minute walking distance with exercise intervention

is free, fast, and customized just for you!

Already a member?

Sign In Now »